Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ: MXCT )

4.050 -0.190 (-4.48%)
Streaming Delayed Price Updated: 2:56 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Baird Global Healthcare Conference
From MaxCyte, Inc
Via GlobeNewswire
Recap: MaxCyte Q1 Earnings
Via Benzinga
Looking Into MaxCyte's Return On Capital Employed
Via Benzinga
MaxCyte's Earnings: A Preview
Via Benzinga
MaxCyte Earnings Perspective: Return On Capital Employed
Via Benzinga
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative... 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market... 
Via Benzinga
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases 
From MaxCyte, Inc
Via GlobeNewswire
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
From MaxCyte, Inc
Via GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ... 
Via Benzinga
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue 
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of... 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards. 
Via InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
7 Hot Stocks to Book Profits In Before 2023
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. 
Via InvestorPlace
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. 
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.